Kiniksa Pharmaceuticals 2025 ARCALYST Net Revenue $677.5 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Kiniksa Pharmaceuticals International provided a corporate update. Key highlights: ARCALYST 2025 net product revenue of $677.5 million, representing ~62% year-over-year growth; ARCALYST 2026 net product revenue expected to be $900 - $920 million; KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; KPL-1161 Phase 1 trial planned to initiate by year end; Cash balance increased by $170.4 million in 2025 to $414.1 million
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KNSA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KNSA
Wall Street analysts forecast KNSA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KNSA is 53.50 USD with a low forecast of 48.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.640
Low
48.00
Averages
53.50
High
60.00
Current: 44.640
Low
48.00
Averages
53.50
High
60.00
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kiniksa Reports $677.5M in 2025 ARCALYST Revenue, 62% Growth
- Significant Revenue Growth: Kiniksa's ARCALYST net product revenue reached $677.5 million in 2025, up 62% from $417 million in 2024, indicating strong market demand in the cardiovascular treatment sector.
- Optimistic Future Outlook: The company expects ARCALYST net product revenue for 2026 to be between $900 million and $920 million, reflecting confidence in sustained product growth and solidifying its position in the biopharmaceutical market.
- Clinical Trial Progress: Data from the Phase 2 trial of KPL-387 is expected in the second half of 2026, which, if successful, could expand the IL-1α and IL-1β inhibition market, addressing the needs of more patients.
- Strong Financial Position: As of the end of 2025, Kiniksa had $414.1 million in cash and short-term investments, an increase of $170.4 million from the previous year, ensuring ample funding for future R&D and market expansion efforts.
Continue Reading
Kinaset Therapeutics Closes $103 Million Series B Financing to Advance Inhaled Asthma Treatment
- Successful Financing: Kinaset Therapeutics has closed a $103 million Series B financing led by RA Capital Management and Forge Life Science Partners, with proceeds aimed at advancing its novel inhaled therapeutic candidate frevecitinib through clinical studies, marking a significant milestone in addressing severe asthma treatment.
- Investor Confidence: The financing attracted participation from several new investors, including EQT Life Sciences and Vivo Capital, demonstrating strong market confidence in Kinaset and its innovative drug, which is expected to accelerate product development timelines.
- Clinical Advancement: Proceeds from this financing will support a Phase 2 dose-ranging clinical study for frevecitinib, aimed at providing new treatment options for patients with severe asthma inadequately controlled by standard therapies, highlighting its significant market potential.
- Board Expansion: Following the financing, executives from RA Capital Management and EQT Life Sciences have joined Kinaset's Board of Directors, enhancing the company's governance structure and industry expertise, which will provide strategic support for future growth.
Continue Reading